Cost-utility Study of a Group of Compensatory Cognitive Remediation in Schizophrenia (Grecco)
Status
Conditions
Treatments
Details and patient eligibility
About
Significant cognitive impairment (executive functions, memory, attention) is common in schizophrenia affecting up to 80% of patients. But pharmacological treatments (typical and atypical antipsychotic) do not have impact on cognitive functioning. For over 20 years, alternative non-pharmacological therapeutics have been developed in schizophrenia. These techniques called cognitive remediation specifically target cognitive deficits. The first cognitive remediation available for patients was designed to stimulate new learning, or relearning, of cognitive tasks, and thus to improve certain deficient domains. These procedures were efficient in improving cognition as measured by neurocognitive tests but their impact on functioning and daily life was weak. In a second time, compensatory remediation has been developed. Compensatory approaches seek to make improvements in the patient's functioning by avoiding areas of impairment and recruiting other intact cognitive domains or by creating a supportive external environment. In recent meta-analysis compensatory remediation has larger effect-size than classical cognitive remediation, with an impact on patients psychosocial functioning. Recently, Dr E. Twamley (University of California) developed and tested a group-based, manualized, compensatory cognitive training intervention.
Compensatory cognitive training (CCT) is a low-tech, brief intervention and is easily transposable in community care. Our team translated this method into French. The investigators planned a cost -utility study between CCT and treatment as usual in schizophrenia patients with less than 10 years of evolution.
Full description
This study will take place over 3 years with a recruitment period of 18 months. After verification of the eligibility criteria and signature of the consent, the patients will be divided into 2 groups by randomization: the intervention group and the control group. The duration of participation of the subjects will be 12 months. Assessments are available in 4 steps (V1 at inclusion, V2 at 3 months, V3 at 6 months and V4 at 12 months). These visits include an assessment of the functioning of patients, symptomatology, quality of life, treatment and care received at all visits, occupational activity and cognitive assessment and social knowledge at V1 and V4.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Diagnostic with schizophrénie
- Less than 10 years of the evolution of the disease
Exclusion criteria
- History of severe cranial trauma and / or neurological pathology with cognitive impairment
- Ongoing participation in another study for treatment of negative or cognitive symptoms
- Ongoing participation in a study on management in psychotherapy for cognitive disorders and negative symptoms
Trial design
Primary purpose
Allocation
Interventional model
Masking
218 participants in 2 patient groups, including a placebo group
Trial contacts and locations
Loading...
Central trial contact
Delphine CD Capdevielle, MD-PhD; Stéphane SR Raffard, PhD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal